81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)
Bibliographic record
Abstract
Significant unmet needs exist for patients with mNSq NSCLC who experience disease progression after treatment with PCT and an ICI. Docetaxel (DOC)-based regimens are commonly used to treat such patients; however, data on the characteristics of and outcomes for those receiving these therapies in the real world are lacking. The objective of this study was to provide a benchmark for survival with present standard-of-care therapies by conducting a retrospective cohort study of real-world patients treated with DOC or DOC plus ramucirumab (DOC+RAM) in the US. The study utilized data from US patients included in the ConcertAI Patient 360 NSCLC database who initiated first-line treatment between 01-Jul-2016 and 31-Dec-2020. Patients who had mNSq NSCLC, an Eastern Cooperative Oncology Group performance status of 0 or 1, and received DOC or DOC+RAM following disease progression after PCT and an ICI (in combination or separately) were eligible. Patients’ demographics and clinical characteristics as well as outcomes (real-world overall survival [OS], progression-free survival [PFS], time to treatment discontinuation [TTD], and time to next treatment [TTNT]) were analyzed. For patients receiving DOC (N=41; mean age: 65 years) or DOC+RAM (N=87; mean age: 64 years), median OS was 6.0 months (95% confidence interval [CI]: 4.8, 11.6) and 5.9 months (95% CI: 4.2, 11.6), respectively. Median PFS was 2.9 months (95% CI: 1.9, 4.6) for DOC and 2.7 months (95% CI: 2.3, 4.6) for DOC+RAM. Median TTD and TTNT were 2.1 months (95% CI: 1.4, 3.4) and 7.4 months (95% CI: 5.7, not estimable [NE]) for DOC and 1.5 months (95% CI: 1.4, 2.1) and 15.2 months (95% CI: 12.3, NE) for DOC+RAM, respectively. Estimates for TTNT should be considered with caution, given that a large number of patients were censored because of death or end of follow-up. This study highlights the poor prognosis for real-world mNSq NSCLC patients who experience disease progression after PCT and ICI. The results can be used to help evaluate novel therapies in this population.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".